TREML2 antibody (PE)

Catalog No. ABIN2663936

Product Details anti-TREML2 Antibody (PE)

Target: TREML2 (Triggering Receptor Expressed On Myeloid Cells-Like 2 (TREML2))

Reactivity: Mouse

Host: Rat

Clonality: Monoclonal

Conjugate: This TREML2 antibody is conjugated to PE

Application: Flow Cytometry (FACS)

Purification: The antibody was purified by affinity chromatography, and conjugated with PE under optimal conditions. The solution is free of unconjugated PE and unconjugated antibody.

Clone: MIH47

Isotype: IgG2a kappa

Application Details

Application Notes: Optimal working dilution should be determined by the investigator.

Restrictions: For Research Use only

Handling

Concentration: 0.2 mg/mL

Buffer: Phosphate-buffered solution, pH 7.2, containing 0.09 % sodium azide.

Preservative: Sodium azide

Precaution of Use: This product contains Sodium azide: a POISONOUS AND HAZARDOUS SUBSTANCE which should be handled by trained staff only.

Handling Advice: Protect from prolonged exposure to light. Do not freeze.

Storage: 4 °C

Storage Comment: The antibody solution should be stored undiluted between 2°C and 8°C.

Target Details for TREML2

Target: TREML2 (Triggering Receptor Expressed On Myeloid Cells-Like 2 (TREML2))

Alternative Name: TLT-2 (TREML2 Products)

Synonyms: TREM-B2V1 antibody, C6orf76 antibody, TLT-2 antibody, TLT2 antibody, dJ238O23.1 antibody, AW049306 antibody, Gm750 antibody, Tlt2 antibody, triggering receptor expressed on myeloid cells like 2 antibody, triggering receptor expressed on myeloid cells-like 2 antibody, TREML2 antibody, Treml2 antibody

Background: Triggering receptor expressed on myeloid cell-like transcript 2 (TLT-2, TREML2) is a type I transmembrane protein in TREM family. It consists of a single extracellular Ig-like domain of the V-type, a transmembrane domain, and a short cytoplasmic domain. TLT-2 is expressed on myeloid , B cells , and macrophages. It was also found to express on CD8+ T cells and activated CD4+ T cells. It regulates innate immune response based on its expression profile, costimulates the activation of T cells. Transduction of TLT-2 into T cells resulted in enhanced IL-2 and IFN-gamma production. It was reported that B3-H7 is a receptor of TLT-2. Blockade of the B7-H3/ TLT-2 pathway with monoclonal antibodies against B7-H3 or TLT-2 efficiently inhibited hypersensitivity response. Further studies are needed to confirm the ligand.